Search
Search Results
-
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic...
-
Graphene as Photothermal Therapeutic Agents
Light-assisted hyperthermic therapy is a promising strategy to treat cancer. Graphene and their derivatives with unique physiochemical properties,...
-
Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity
BackgroundPancreatic ductal adenocarcinoma (PDAC) is a profoundly aggressive and fatal cancer. One of the key factors defining its aggressiveness and...
-
Animal Models for Prostate Cancer Research: A Mechanistic Outlook on the Challenges and Recent Progress
Molecular pathogenesis of prostate cancer (PCa) still remains poorly understood in human. Difficulties in understanding of prostate oncogenesis and...
-
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we...
-
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
BackgroundSurvival rates for ovarian cancer remain poor, and monitoring and prediction of therapeutic response may benefit from additional markers....
-
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling
BackgroundNutritional support, including nutritional counseling and oral nutritional supplements (ONS), has been recommended as a first-line strategy...
-
EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma
AbstractHepatocellular carcinoma (HCC) is an aggressive malignancy, and its effective treatment has been hampered by drug resistance. Extracellular...
-
Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance
To date, the use of immune checkpoint inhibitors has proven largely ineffective in patients with advanced pancreatic ductal adenocarcinoma. A...
-
Available Preclinical Tools for Neuroblastoma
Neuroblastoma is the most predominant and deadly cancer in infants and in young children and contributes significantly to childhood cancer deaths....
-
The role of m6A methylation in therapy resistance in cancer
Cancer therapy resistance is the main cause of cancer treatment failure. The mechanism of therapy resistance is a hot topic in epigenetics. As one of...
-
Hypoxia-Induced Stress Responses in Cancer and Cancer Stem Cells
Oxygen is highly critical for the survival of complex organisms and lack of oxygen (hypoxia) promotes stress and death of the organism. However,...
-
Small extracellular vesicle TGF-β in cancer progression and immune evasion
Transforming growth factor-β (TGF-β) is a well-known cytokine that controls various processes in normal physiology and disease context. Strong...
-
Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis
Cancer divergence has many facets other than being considered a genetic term. It is a tremendous challenge to understand the metastasis and therapy...
-
Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation
Most of the current antitumor therapeutics were developed targeting the cancer cells only. Unfortunately, in the majority of tumors, this...
-
A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer
BackgroundPHI-101 is an orally available, selective checkpoint kinase 2 (Chk2) inhibitor. PHI-101 has shown anti-tumour activity in ovarian cancer...
-
The health risks of dysphagia for patients with head and neck cancer: a multicentre prospective observational study
It is well known that malnutrition is a frequent co-morbidity in cancer patients, especially in those with head and neck neoplasms. This may be due...
-
MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells
BackgroundChemotherapy is one of the most common treatment options for breast cancer (BC) patients. However, about half of the BC patients are...
-
Revisiting reactive oxygen species production in hypoxia
Cellular responses to hypoxia are crucial in various physiological and pathophysiological contexts and have thus been extensively studied. This has...
